Cargando…

Model based assessment of food and acid reducing agent effects on oral absorption of mezigdomide (CC‐92480), a novel cereblon E3 ligase modulator

Mezigdomide is a novel cereblon E3 ligase modulator (CELMoD) agent with enhanced autonomous cell‐killing activity in multiple myeloma (MM) cells, and promising immunomodulatory and antitumor activity in patients with MM. We developed a population pharmacokinetics (PKs) model for mezigdomide in healt...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wu, Fan, Liu, Liangang, Gaudy, Allison, Wang, Xiaomin, Carayannopoulos, Leon, Pourdehnad, Michael, Lamba, Manisha
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10583261/ https://www.ncbi.nlm.nih.gov/pubmed/37705327 http://dx.doi.org/10.1002/psp4.13024

Ejemplares similares

P868: MEZIGDOMIDE (MEZI) PLUS DEXAMETHASONE (DEX) IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): RESULTS FROM THE DOSE-EXPANSION PHASE OF THE CC-92480-MM-001 TRIAL
por: Bahlis, Nizar J, et al.
Publicado: (2023)

First‐in‐Human, Single‐ and Multiple‐Ascending‐Dose Studies in Healthy Subjects to Assess Pharmacokinetics, Pharmacodynamics, and Safety/Tolerability of Iberdomide, a Novel Cereblon E3 Ligase Modulator
por: Ye, Ying, et al.
Publicado: (2020)

Drug‐Drug Interaction Study to Assess the Effect of Cytochrome P450 Inhibition and Induction on the Pharmacokinetics of the Novel Cereblon Modulator Avadomide (CC‐122) in Healthy Adult Subjects
por: Ogasawara, Ken, et al.
Publicado: (2019)

Safety, Pharmacokinetics, and Pharmacodynamics of CC‐90001 (BMS‐986360), a c‐Jun N‐terminal Kinase Inhibitor, in Phase 1 Studies in Healthy Participants
por: Ye, Ying, et al.
Publicado: (2022)

Population Pharmacokinetics of CC-122
por: Cheng, Yiming, et al.
Publicado: (2021)

Iberdomide (CC-220) is a potent cereblon E3 ligase modulator with antitumor and immunostimulatory activities in lenalidomide- and pomalidomide-resistant multiple myeloma cells with dysregulated CRBN
por: Bjorklund, Chad C., et al.
Publicado: (2019)

The E3 ubiquitin ligase component, Cereblon, is an evolutionarily conserved regulator of Wnt signaling
por: Shen, Chen, et al.
Publicado: (2021)

The novel cereblon modulator CC-885 inhibits mitophagy via selective degradation of BNIP3L
por: Hao, Bing-bing, et al.
Publicado: (2020)

Cereblon versus VHL: Hijacking E3 ligases against each other using PROTACs
por: Girardini, Miriam, et al.
Publicado: (2019)

Rapid Progress in the Use of Immunomodulatory Drugs and Cereblon E3 Ligase Modulators in the Treatment of Multiple Myeloma
por: Charliński, Grzegorz, et al.
Publicado: (2021)

Modeling the CRL4A ligase complex to predict target protein ubiquitination induced by cereblon-recruiting PROTACs
por: Bai, Nan, et al.
Publicado: (2022)

Chemical Ligand Space of Cereblon
por: Boichenko, Iuliia, et al.
Publicado: (2018)

Cereblon modulator iberdomide induces degradation of the transcription factors Ikaros and Aiolos: immunomodulation in healthy volunteers and relevance to systemic lupus erythematosus
por: Schafer, Peter H, et al.
Publicado: (2018)

Caspase-8 Inhibition Prevents the Cleavage and Degradation of E3 Ligase Substrate Receptor Cereblon and Potentiates Its Biological Function
por: Zhou, Liang, et al.
Publicado: (2020)

A Cereblon Modulator CC-885 Induces CRBN- and p97-Dependent PLK1 Degradation and Synergizes with Volasertib to Suppress Lung Cancer
por: Li, Lifeng, et al.
Publicado: (2020)

Mouse Monoclonal Antibodies Generated from Full Length Human Cereblon: Detection of Cereblon Protein in Patients with Multiple Myeloma
por: Chang, Xiubao, et al.
Publicado: (2017)

Exposure-response analysis to assess the concentration–QTc relationship of CC-122
por: Li, Yan, et al.
Publicado: (2016)

Structural Dynamics of the Cereblon Ligand Binding Domain
por: Hartmann, Marcus D., et al.
Publicado: (2015)

Structural basis of thalidomide enantiomer binding to cereblon
por: Mori, Tomoyuki, et al.
Publicado: (2018)

Tubulin Resists Degradation by Cereblon-Recruiting PROTACs
por: Gasic, Ivana, et al.
Publicado: (2020)

UDP-glucose, cereblon-dependent proinsulin degrader
por: Cho, Jaeyong, et al.
Publicado: (2022)

The Cullin 4A/B-DDB1-Cereblon E3 Ubiquitin Ligase Complex Mediates the Degradation of CLC-1 Chloride Channels
por: Chen, Yi-An, et al.
Publicado: (2015)

Mitochondrial cereblon functions as a Lon-type protease
por: Kataoka, Kosuke, et al.
Publicado: (2016)

In silico analysis of enantioselective binding of immunomodulatory imide drugs to cereblon
por: Murai, Takahiro, et al.
Publicado: (2016)

Susceptibility of pentylenetetrazole-induced seizures in mice with Cereblon gene knockout
por: Jeon, Seung-Je, et al.
Publicado: (2020)

UDP-Glucose: A Cereblon-Dependent Glucokinase Protein Degrader
por: Cho, Jaeyong, et al.
Publicado: (2022)

Targeted protein degradation bypassing cereblon and von Hippel-Lindau
por: Lu, Wenchao
Publicado: (2023)

Phase Ib study of combinations of avadomide (CC‐122), CC‐223, CC‐292, and rituximab in patients with relapsed/refractory diffuse large B‐cell lymphoma
por: Ribrag, Vincent, et al.
Publicado: (2022)

The Casein kinase 1α agonist pyrvinium attenuates Wnt-mediated CK1α degradation via interaction with the E3 ubiquitin ligase component Cereblon
por: Shen, Chen, et al.
Publicado: (2022)

UBE2G1 governs the destruction of cereblon neomorphic substrates
por: Lu, Gang, et al.
Publicado: (2018)

CRL4-Cereblon complex in Thalidomide Embryopathy: a translational investigation
por: Kowalski, Thayne Woycinck, et al.
Publicado: (2020)

Disordered region of cereblon is required for efficient degradation by proteolysis-targeting chimera
por: Kim, Kidae, et al.
Publicado: (2019)

Data for positive selection test and co-evolutionary analysis on mammalian cereblon
por: Onodera, Wataru, et al.
Publicado: (2019)

Antiangiogenic Activity and in Silico Cereblon Binding Analysis of Novel Thalidomide Analogs
por: Peach, Megan L., et al.
Publicado: (2020)

Molecular Mechanisms of Cereblon-Interacting Small Molecules in Multiple Myeloma Therapy
por: Costacurta, Matteo, et al.
Publicado: (2021)

Long-term depletion of cereblon induces mitochondrial dysfunction in cancer cells
por: Park, Seulki, et al.
Publicado: (2021)

Cereblon-Recruiting PROTACs: Will New Drugs Have to Face Old Challenges?
por: Cieślak, Marcin, et al.
Publicado: (2023)

Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide
por: Lopez-Girona, A, et al.
Publicado: (2012)

Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide
por: Lopez-Girona, A, et al.
Publicado: (2012)

Humanized cereblon mice revealed two distinct therapeutic pathways of immunomodulatory drugs
por: Gemechu, Yohannes, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_cb63plo0n5le5lmni9d0hf4aah